To address healthcare challenges across the
world, we unite a biotech spirit with the strength of a successful
pharmaceutical business. The result is a biopharmaceutical company
combining science, passion, and expertise to improve health and
healthcare in new ways. Making a remarkable impact in people's lives is
more than our promise. It's our purpose.
Advaxis is a
clinical-stage biotechnology company developing multiple cancer
immunotherapies based on its proprietary platform intended to redirect
the immune system to kill cancer. The Advaxis Lm-LLO technology,
using bioengineered live attenuated Listeria monocytogenes bacteria, is
the only known cancer immunotherapy agent shown in preclinical studies
to both generate cancer fighting T-cells directed against a cancer
antigen and neutralize Tregs and MSDCs, that protect the tumor
microenvironment from immunologic attack and contribute to tumor growth.
Agenus is an immuno-oncology company driven by innovation. Our goal is to treat
cancers with novel combinations utilizing our unique portfolio of
checkpoint antibodies, tumor microenvironment modifiers, vaccines and
adjuvants. In addition to a broad portfolio, we have an accomplished
team of scientists, novel technology platforms and fully-integrated
end-to-end capabilities from discovery to GMP manufacturing. With our
remarkable combination of science and people, we believe that we are
uniquely positioned to bring curative treatments to cancer patients.
Amgen is a global biotechnology
company that discovers, develops, manufactures and markets important
human therapeutics based on advances in cellular and molecular biology.
Bayer is a
world-class innovation company with a 150-year history. Our scientific
successes are intended to help improve people’s lives. At the same time,
our innovations form the basis for sustainable and profitable business
activity and are the key to maintaining or achieving leadership
positions in all of our markets.
Our products are
helping to address some of today’s biggest challenges, including global
population growth, an aging society and the need to make efficient –
and, wherever possible, sustainable – use of natural resources.
are improving people’s quality of life by preventing, alleviating or
are helping to provide an adequate supply of high-quality food, feed and
high-tech polymer materials are making significant contributions in
areas such as energy and resource efficiency for mobility, construction
and home living.
with our mission “Bayer: Science For A Better Life,” we aim to improve
people’s quality of life. For this endeavor, we focus on our core
competency of developing and successfully commercializing innovative
products and solutions based on scientific knowledge.
Bristol-Myers Squibb is the
world leader in providing life-saving
and life-extending therapies for people with cancer. All of the
company's considerable resources and expertise in oncology are
marshaled toward the single goal of providing safer and more
effective anticancer medicines. The mission of Bristol-Myers
Squibb Oncology is to extend and enhance the lives of people
living with cancer.
Caris Life Sciences® develops and delivers
innovative molecular diagnostic, prognostic and theranostic
services. Molecular Intelligence™, from Caris Life Sciences, is
the world’s foremost evidence-based tumor profiling service designed to
provide oncologists with the most relevant, clinically-actionable and
individualized treatment information to personalize cancer care for all
solid tumors. The company’s Carisome™ platform, currently under
development, is a proprietary, blood-based testing technology for
diagnosis, prognosis and theranosis of cancer and other complex
Corporation (Nasdaq:CELG) is a global biopharmaceutical company that is
helping healthcare providers turn incurable cancers and other serious
conditions into chronic, manageable diseases through innovative
therapies. This dedication to medical progress goes hand-in-hand with
our industry-leading patient support and access programs. Together,
these aspects form the core of our commitment to patients worldwide.
Clovis is a biopharmaceutical company focused on acquiring,
developing and commercializing cancer treatments in the United
States, Europe and other international markets. Our development
programs are targeted at specific subsets of cancer, combining
personalized medicine with companion diagnostics to direct
therapeutics to those patients most likely to benefit from them.
Genentech is a leading
biotechnology company that discovers, develops, manufactures and
commercializes biotherapeutics for significant
unmet medical needs. Genentech manufactures and commercializes several
major oncology drugs include Herceptin, Rituxan, Avastin and
Genmab is an
international biotechnology company specializing in the creation and
development of differentiated antibody therapeutics for the treatment of
ImmunoGen, Inc. develops targeted
anticancer therapeutics. The Company’s ADC technology uses a
tumor-targeting engineered antibody to deliver one of ImmunoGen's highly
potent cancer-cell killing agents specifically to tumor cells; the
Company has also developed antibodies with anticancer activity of their
own. The most advanced compound with ImmunoGen’s ADC technology is
Roche’s Kadcyla®. Additional compounds are in clinical
testing by ImmunoGen and through the Company’s partnerships with Amgen,
Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen
can be found at
For more than 30 years, Janssen Biotech, Inc. has
delivered on the promise of new treatments and ways to improve the
health of individuals with serious disease. Built upon a rich legacy of
innovative firsts, Janssen Biotech, Inc. pursues patient-focused
solutions in the therapeutic areas of immunology and oncology. With the
same unwavering passion for new challenges, we dedicate ourselves to
delivering solutions for these disease states where unmet needs continue
to exist. Rooted in rich scientific collaborations and
community-based relationships, we have access to some of the top minds
in science today, allowing us to advance the treatment of patients
through our innovative medicines. Our discoveries lead us not only to
new treatments, but also to new ways to empower patients and expand
their access to quality care. For more about Janssen Biotech, Inc.
Eli Lilly and Company is a
corporation and is developing a growing portfolio of best-in-class
pharmaceutical products by applying the latest research from its own
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Indiana, Lilly provides
answers – through medicines and information – for some of the world’s
most urgent medical needs.
Lilly Oncology is committed to
providing comprehensive healthcare solutions – answers that matter –
for oncologists and cancer patients around
the world through the discovery and development of breakthrough cancer
Oncology is dedicated to innovative approaches, practical
solutions and valuable medical therapies that satisfy the
current and emerging needs of the Oncology community. Current
marketed products in oncology are Gleevec™, Femara™, Zometa™,
research from his basement laboratory has evolved to become an
international oncology company with more than 450 employees and
operations in the U.S., Europe and Asia.
Optune® – our Tumor Treating Fields delivery system for glioblastoma (GBM)
– in the United States for the treatment of recurrent glioblastoma in
2011. In October 2015, we received U.S. Food and Drug Administration
(FDA) approval to market and sell Optune for the treatment of adult
patients with newly diagnosed GBM in combination with temozolomide. We
actively market for that indication in the United States, Germany and
The science of
Tumor Treating Fields has the potential to extend beyond GBM. We have
five ongoing or completed phase 2 pilot trials for brain metastases,
non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer
and mesothelioma. We presented our phase 2 pilot data in pancreatic and
ovarian cancers at our research and development day on Dec. 12, 2016. In
2016, we began our phase 3 pivotal trial in brain metastases originating
from NSCLC. In 2017, we started our phase 3 pivotal trial in NSCLC.
Internationally, more than 20 institutions are studying the effects of
Tumor Treating Fields in cancer treatment.
began with a patient-forward approach that continues to drive our
mission today. With more than 15 years of research and many significant
milestones, we have established ourselves as an innovator in oncology
dedicated to improving the lives of cancer patients.
Pfizer is a research-based
global pharmaceutical company dedicated to helping people live longer,
healthier lives. It invests more than $2 billion annually in research,
searching for treatments and cures for cancer, osteoporosis, diabetes,
Alzheimer's disease, arthritis, heart disease, sexual dysfunction, and
a wide variety of other diseases. Pfizer is also a leader in animal
health, offering medicines for companion and farm animals, and in
consumer health care products.
We are a leading science and technology company that delivers
life-transforming medicines for serious diseases.
Founded by physician-scientists nearly 30 years ago, our science-driven
approach has resulted in six FDA-approved medicines and numerous product
candidates in a range of diseases, including cancer, asthma, pain and
In addition to our medicines, our innovations include the VelociSuite®
technologies, world-class manufacturing operations, one of the largest
human sequencing efforts in the world and rapid response technologies
being used for global good.
TESARO is an oncology-focused biopharmaceutical
company dedicated to improving the lives of cancer patients by
acquiring, developing and commercializing safer and more effective
Vascular Biogenics Ltd.,
operating as VBL Therapeutics, is a clinical stage biopharmaceutical
company focused on the discovery, development and commercialization of
first-in-class treatments for cancer. The Company’s lead oncology
product candidate, VB-111, is a first-in-class, targeted anti-cancer
gene-therapy agent that is positioned to treat a wide range of solid
tumors. VB-111 is conveniently administered as an IV infusion once every
two months. The mechanism of VB-111 combines blockade of tumor
vasculature with an anti-tumor immune response. This mechanism retains
activity regardless of baseline tumor mutations or the identity of the
pro-angiogenic factors secreted by the tumor. VB-111 is currently being
studied in a Phase 3 pivotal trial for Recurrent Glioblastoma (rGBM).
The trial is being conducted under an FDA Special Protocol Assessment
(SPA), and VB-111 has obtained fast track and Orphan designations.